Time filter

Source Type

São Paulo, Brazil

Rocha-e-Silva M.,Hospital das Clinicas FMUSP
Arquivos Brasileiros de Cardiologia | Year: 2011

Over the period 2009 - 2010, Clinics has published a relatively large number of original studies dealing with the cardiovascular and pulmonary system. Twenty of these have attracted significant numbers of citations within this relatively short time span. This short review covers these aspects of recent research with direct interest to cardiologists. Articles were grouped under three headings: Cardiology, Pneumology and Multidisciplinary. Source

Nicolini F.E.,Hopital edouard Herriot | Masszi T.,St. Istvan and St. Laszlo Hospital | Shen Z.,Shanghai Ruijin Hospital | Gallagher N.J.,Novartis | And 6 more authors.
Leukemia and Lymphoma | Year: 2012

Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and safety data for patients in CML-AP (n = 181) or blast crisis (CML-BC) (n = 190; myeloid BC, 133; lymphoid BC, 50; unknown, seven) enrolled in an expanded access phase IIIb study. Non-hematologic adverse events were mostly mild to moderate. Drug-related myelosuppression was generally manageable with dose reductions or interruptions and infrequently led to discontinuation of nilotinib. Drug-related grade 3/4 elevations in serum bilirubin and lipase were infrequent. While an analysis of efficacy was not the primary objective of this study, significant hematologic and cytogenetic responses were observed. These results support the safety and efficacy of nilotinib in patients with advanced CML in AP and BC. © 2012 Informa UK, Ltd. Source

Discover hidden collaborations